Under federal regulations, compounding pharmacies can produce these medications to ensure patients continue to have access to necessary treatments during supply disruptions
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
A subset of patients achieved 15% or 20% BMI reductions by 12 months (17% and 9% of patients, respectively)
If youre unsure whether you received a full dosefor example, if the pen didnt complete its cycle or medication leaked significantlycontact your healthcare provider for guidance